A Phase 1 interventional study of TAK-881 and SC Investigational Needle Sets in Healthy Volunteers, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Takeda · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of this study is to check how well healthy adults can tolerate TAK-881 with different dosing schedules.
During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous [SC] infusion) on Day 1 at a lower dose level followed by participants receiving multiple infusion of higher dose levels.
Participants will be in the study for approximately 19 weeks including screening period and follow-up (End of Treatment [EOT]).
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive TAK-881, subcutaneous (SC) injection, 0.15 grams per kilogram (g/kg) on Day 1, 0.3 g/kg on Day 8, 0.6 g/kg on Days 22 and 50 in ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 0.6 g/kg on Days 1, 29 and 57 in no ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 0.25 g/kg on Days 1 and 8, 0.5 g/kg on Day 15, 0.75 g/kg on Day 29 and 1.0 g/kg on Day 50 in ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 0.25 g/kg on Day 1, 0.5 g/kg on Day 8, 1.0 g/kg on Days 22 and 50 in ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 1.0 g/kg on Days 1, 29 and 57 in no ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 0.5 g/kg on Days 1 and 8, 1.0 g/kg on Day 15, 1.5 g/kg on Day 29 and 2.0 g/kg on Day 50 in ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 0.5 g/kg on Day 1, 1.0 g/kg on Day 8, 2.0 g/kg on Days 22 and 50 in ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
Participants will receive TAK-881, SC injection, 2.0 g/kg, on Days 1, 29 and 57 in no ramp-up dosing manner.
Biological: TAK-881 · Device: SC Investigational Needle Sets
TAK-881 SC injection.
Also known as: Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)
The single-use only SC needle set will be used to administer TAK-881 to the target depth below the skin surface. One needle set (single or bifurcated) will be used per infusion.
Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment
A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any treatment-emergent adverse events (TEAEs) related to TAK-881. An infusion was considered to be tolerable if the participant had tolerated both the recombinant human hyaluronidase (rHuPH20) and immune globulin subcutaneous (IGSC) 20 percent (%) components of TAK-881. The number of participants who tolerated all initiated infusions by TAK-881 treatment were reported in this outcome measure.
Time frame: Up to Day 57
Number of Tolerable Infusions by TAK-881 Treatment
A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any TEAEs related to TAK-881. The number of tolerable infusions by TAK-881 treatment were reported in this outcome measure.
Time frame: Up to Day 57
Number of Participants With TEAEs
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the investigational product (IP), whether or not the occurrence was considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the IP. A TEAE was defined as any AE that was not present prior to the initiation of the treatments or any pre-existing AE that worsened in either intensity or frequency after receiving the first dose of trial intervention in this trial through 98 (±7) days after the last dose of trial intervention. Number of participants with TEAEs were reported in this outcome measure.
Time frame: From start of study drug administration up to end of trial (EOT) (up to Week 16)
Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Clinical laboratory parameters included analysis of serum chemistry, hematology, coagulation and urinalysis. Clinical significance of laboratory values was determined at the investigator's discretion.
Time frame: From start of study drug administration up to EOT (up to Week 16)
Number of Participants With Clinically Significant Changes in Vital Sign Parameters
Vital signs parameters included measurement of pulse rate, blood pressure, body temperature and respiratory rate. Clinical significance of vital signs was determined at the investigator's discretion.
Time frame: From start of study drug administration up to EOT (up to Week 16)
Number of Participants With Positive Binding Antibodies to rHuPH20
The binding antibodies were considered as "positive" if corresponding titer was \>= 1:160. Number of participants with positive binding antibodies to rHuPH20 with titer \>=1:160 were reported in this outcome measure.
Time frame: Up to Week 16
Number of Participants With Neutralizing Antibodies to Anti-rHuPH20
All participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the screening and confirmatory binding assay). Post-dose samples with antibody titers \>=1 :160 were analyzed for the presence of neutralizing-ADA using a validated assay based on neutralization of rHuPH20 activity. Number of participants with neutralizing antibodies to anti-rHuPH20 were reported in this outcome measure.
Time frame: Up to Week 16
Participants took part in the study at 1 investigative site in the United States from 22 April 2025 to 27 September 2025.
| Milestone | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 7 | 8 | 6 | 8 | 8 | 7 | 7 | 4 |
| Not completed | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 4 |
| Withdrew: Non-compliance | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any treatment-emergent adverse events (TEAEs) related to TAK-881. An infusion was considered to be tolerable if the participant had tolerated both the recombinant human hyaluronidase (rHuPH20) and immune globulin subcutaneous (IGSC) 20 percent (%) components of TAK-881. The number of participants who tolerated all initiated infusions by TAK-881 treatment were reported in this outcome measure.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Who Tolerated All Initiated Infusions by TAK-881 Treatment | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) | 8 (63 to 100) |
A tolerable infusion was considered to have occurred if an infusion was completed without interruption (discontinuing the infusion, or infusion rate reduction) due to any TEAEs related to TAK-881. The number of tolerable infusions by TAK-881 treatment were reported in this outcome measure.
| number of infusions | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Number of Tolerable Infusions by TAK-881 Treatment | 31 (89 to 100) | 24 (86 to 100) | 35 (90 to 100) | 32 (89 to 100) | 24 (86 to 100) | 46 (92 to 100) | 42 (92 to 100) | 31 (89 to 100) |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of the investigational product (IP), whether or not the occurrence was considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the IP. A TEAE was defined as any AE that was not present prior to the initiation of the treatments or any pre-existing AE that worsened in either intensity or frequency after receiving the first dose of trial intervention in this trial through 98 (±7) days after the last dose of trial intervention. Number of participants with TEAEs were reported in this outcome measure.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With TEAEs | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Clinical laboratory parameters included analysis of serum chemistry, hematology, coagulation and urinalysis. Clinical significance of laboratory values was determined at the investigator's discretion.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Serum Chemistry | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Hematology | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 |
| Coagulation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Urinalysis | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Vital signs parameters included measurement of pulse rate, blood pressure, body temperature and respiratory rate. Clinical significance of vital signs was determined at the investigator's discretion.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Pulse Rate | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood Pressure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Body Temperature | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Respiratory Rate | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The binding antibodies were considered as "positive" if corresponding titer was \>= 1:160. Number of participants with positive binding antibodies to rHuPH20 with titer \>=1:160 were reported in this outcome measure.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Number of Participants With Positive Binding Antibodies to rHuPH20 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
All participants were monitored for the formation of anti-rHuPH20 antibodies using validated anti-rHuPH20 antibody detection assay (also known as the screening and confirmatory binding assay). Post-dose samples with antibody titers \>=1 :160 were analyzed for the presence of neutralizing-ADA using a validated assay based on neutralization of rHuPH20 activity. Number of participants with neutralizing antibodies to anti-rHuPH20 were reported in this outcome measure.
| Participants | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Participants with Positive Neutralizing Antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with Negative Neutralizing Antibodies | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Collected over From start of study drug administration up to EOT (up to Week 16). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: TAK-881 Ramp-up Schedule B | 0/8 (0%) | 1/8 (12.5%) | 8/8 (100%) |
| Cohort 1: TAK-881 No Ramp-up Schedule C | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 2: TAK-881 Ramp-up Schedule A | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 2: TAK-881 Ramp-up Schedule B | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 2: TAK-881 No Ramp-up Schedule C | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 3: TAK-881 Ramp-up Schedule A | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 3: TAK-881 Ramp-up Schedule B | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Cohort 3: TAK-881 No Ramp-up Schedule C | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Event | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 | 0/8 |
| Event | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C |
|---|---|---|---|---|---|---|---|---|
| Infusion site erythemaGeneral disorders | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 | 7/8 | 8/8 |
| Infusion site painGeneral disorders | 5/8 | 8/8 | 5/8 | 4/8 | 7/8 | 8/8 | 6/8 | 6/8 |
| Infusion site swellingGeneral disorders | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 | 8/8 |
| HeadacheNervous system disorders | 1/8 | 3/8 | 4/8 | 5/8 | 4/8 | 5/8 | 6/8 | 7/8 |
| Infusion site indurationGeneral disorders | 1/8 | 2/8 | 2/8 | 3/8 | 2/8 | 7/8 | 1/8 | 2/8 |
| Infusion site pruritusGeneral disorders | 3/8 | 5/8 | 3/8 | 2/8 | 2/8 | 7/8 | 7/8 | 5/8 |
| Infusion site warmthGeneral disorders | 1/8 | 1/8 | 0/8 | 5/8 | 2/8 | 6/8 | 2/8 | 3/8 |
| DizzinessNervous system disorders | 0/8 | 1/8 | 0/8 | 0/8 | 0/8 | 0/8 | 3/8 | 0/8 |
| Infusion site discomfortGeneral disorders | 0/8 | 3/8 | 0/8 | 0/8 | 0/8 | 2/8 | 1/8 | 2/8 |
| Infusion site haemorrhageGeneral disorders | 0/8 | 0/8 | 0/8 | 1/8 | 2/8 | 3/8 | 0/8 | 0/8 |
The safety analysis set (SAS) included all participants who received any amount of TAK-881.
| Age, Categorical(Participants) | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 64 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 8 | 7 | 4 | 5 | 3 | 4 | 2 | 37 |
| Male | 4 | 0 | 1 | 4 | 3 | 5 | 4 | 6 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 7 | 8 | 8 | 7 | 7 | 8 | 8 | 60 |
| Not Hispanic or Latino | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: TAK-881 Ramp-up Schedule B | Cohort 1: TAK-881 No Ramp-up Schedule C | Cohort 2: TAK-881 Ramp-up Schedule A | Cohort 2: TAK-881 Ramp-up Schedule B | Cohort 2: TAK-881 No Ramp-up Schedule C | Cohort 3: TAK-881 Ramp-up Schedule A | Cohort 3: TAK-881 Ramp-up Schedule B | Cohort 3: TAK-881 No Ramp-up Schedule C | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 0 | 2 | 0 | 1 | 2 | 9 |
| White | 7 | 6 | 7 | 8 | 6 | 8 | 6 | 6 | 54 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2025 to primary completion in Sep 2025, 5 months.
Results were first posted in Aug 2026, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.